The Helsinki Heart Study: central findings and clinical implications

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Lipid Metabolism

Background:

• Coronary heart disease (CHD) remains a leading cause of mortality.
• Lipoprotein profiles, including low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, are key risk factors for CHD.
• Primary prevention strategies aim to reduce CHD incidence in asymptomatic individuals.

Purpose of the Study:

• To evaluate the efficacy of gemfibrozil in primary prevention of coronary heart disease.
• To test the hypothesis that altering serum lipid concentrations (lowering LDL and very low-density lipoprotein (VLDL), raising HDL) protects against CHD.
• To assess the clinical implications of gemfibrozil treatment on cardiovascular outcomes.

Main Methods:

• A controlled primary prevention trial design was employed.
• Participants received either gemfibrozil or a placebo.
• Serum lipid levels (LDL, VLDL, HDL) were monitored throughout the study.

Main Results:

• Gemfibrozil treatment led to significant reductions in LDL and VLDL cholesterol concentrations.
• A notable increase in high-density lipoprotein (HDL) cholesterol was observed in the gemfibrozil group.
• The study demonstrated a statistically significant reduction in coronary heart disease events in subjects treated with gemfibrozil.

Conclusions:

• Gemfibrozil effectively modifies lipid profiles, lowering atherogenic lipoproteins and increasing protective HDL.
• The findings support the use of gemfibrozil as a primary prevention strategy for coronary heart disease.
• Altering lipoprotein concentrations through pharmacologic intervention can significantly reduce cardiovascular risk.